Skip to Content
Merck

Key Documents

View All Documentation

N4382

Nalidixic acid sodium salt

DNA gyrase inhibitor, powder

Synonym(s):

1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid sodium salt

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C12H11N2NaO3
CAS Number:
3374-05-8
Molecular Weight:
254.22
NACRES:
NA.77
PubChem Substance ID:
24278589
UNSPSC Code:
12352106
EC Number:
222-159-7
MDL number:
MFCD00064376
Beilstein/REAXYS Number:
3580062
Form:
powder
Quality level:
200
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Nalidixic acid sodium salt, powder

Quality Level

200

form

powder

antibiotic activity spectrum

Gram-negative bacteria, Gram-positive bacteria

mode of action

DNA synthesis | interferes, enzyme | inhibits

originator

Sanofi Aventis

SMILES string

[Na+].CCN1C=C(C([O-])=O)C(=O)c2ccc(C)nc12

InChI

1S/C12H12N2O3.Na/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14;/h4-6H,3H2,1-2H3,(H,16,17);/q;+1/p-1

InChI key

ROKRAUFZFDQWLE-UHFFFAOYSA-M

General description

Nalidixic acid is a quinolone and can block the activity of bacterial topoisomerase type II enzyme, thereby stopping bacterial replication. It is a potential antibacterial agent against Gram-negative bacteria than Gram-positive bacteria. Nalidixic acid has been studied in the management of urinary tract infections.
Chemical structure: quinolone

Application

Nalidixicacid has been used to treat the bacterial cultures to study itsresistance on Salmonella enterica and SalmonellaTyphimurium.

Biochem/physiol Actions

Nalidixic acid sodium salt is an inhibitor of bacterial DNA polymerase (DNA gyrase) and avian myeloblastoma virus reverse transcriptase. Inhibits nucleic acid and protein synthesis in Saccharomyces cerevisiae.

Features and Benefits

This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Still not finding the right product?

Explore all of our products under Nalidixic acid sodium salt

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Warning

hcodes

H302,H351

Hazard Classifications

Acute Tox. 4 Oral - Carc. 2

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000491339
0000491339
0000491346
0000491346
0000480610

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Nalidixic Acid
Acta Entomologica Silesiana, 154-175 (1979)
Daniel Hernandez-Patlan et al.
Frontiers in veterinary science, 6, 108-108 (2019-05-21)
Decreases in the use of antibiotics and anticoccidials in the poultry industry have risen the appearance of necrotic enteritis (NE). The purpose of this study was to evaluate the effect of a Bacillus direct-fed microbial (DFM) on growth performance, intestinal
Thu D M Pham et al.
MedChemComm, 10(10), 1719-1739 (2019-12-06)
The quinolone antibiotics arose in the early 1960s, with the first examples possessing a narrow-spectrum of activity with unfavorable pharmacokinetic properties. Over time, the development of new quinolone antibiotics has led to improved analogues with an expanded spectrum and high
View All Related Papers